Iravani and co-workers showed that expression of claudin-12 is upregulated in estrogen receptor (ER)-negative breast cancer and its expression is associated with poor prognosis, indicating that claudin-12 may serve as a marker for predicting the survival in this cancer subtype [79]. This evidence concerns the gene CLDN12 and cancer.